Compare iShares Core Growth Allocation ETF (AOR) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core Growth Allocation ETF vs Moderna, Inc. — how do they compare? iShares Core Growth Allocation ETF trades at $69.87, while Moderna, Inc. trades at $60.45 (market cap $24.18B). The key difference: iShares Core Growth Allocation ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| AOR | MRNA | |
|---|---|---|
52-Week High | $70.12 | $81.80 |
52-Week Low | $62.26 | $22.36 |
Market Cap | — | $24.18B |
Sector | — | Health |
Enterprise Value | — | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
